Merus (NASDAQ:MRUS) Azioni

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $83 price target.

News

Price Target

Reiteration

Analyst Ratings

MRUS

Needham Reiterates Buy on Merus, Maintains $83 Price Target

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $73 to $70.

B of A Securities Maintains Buy on Merus, Lowers Price Target to $70

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $85 to $83.

Needham Maintains Buy on Merus, Lowers Price Target to $83

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(3.35) per share which beat the analyst consensus estimate of $(3.80) by 11.84 percent. The company reported quarterly sales of $36.133 which missed the analyst consensus estimate of $38.544 million by 100.00 percent.

Earnings

Earnings Beats

Earnings Misses

Merus FY 2024 GAAP EPS $(3.35) Beats $(3.80) Estimate, Sales $36.133 Miss $38.544M Estimate

Shares of Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) are trading higher Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to <a href="https://www.benzinga.com/25/01/42961654/whats-going-on-with-merus-stock-monday">petosemtamab in combination with pembrolizumab.</a>
What To Know: The designation applies to the first-line treatment of adult patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma (r/m HNSCC) with a combined positive score of at least 1.
This marks the second BTD for petosemtamab, following an earlier designation for patients with r/m HNSCC whose disease had progressed after treatment with platinum-based chemotherapy and an anti-PD-1 antibody. The new designation is based on updated data from an ongoing phase 1/2 clinical trial, which initially showed a 67% response rate among 24 evaluable patients.
Breakthrough Therapy designation is intended to expedite the development and review of drugs that show substantial improvement over existing treatments for serious conditions. This status will allow Merus to work closely with the FDA, accelerating regulatory discussions and potentially leading to a faster approval process. 
MRUS Price Action: Merus shares were up 5.40% at $42.37 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png" alt="" class="wp-image-787550" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43761300/intel-could-be-split-in-two-as-broadcom-and-tsmc-explore-deals-trump-white-house-resists-foreign-ownership-report">Intel Could Be Split In Two As Broadcom And TSMC Explore Deals, Trump White House Resists Foreign Ownership: Report</a></li>
</ul>
Image via Shutterstock.

Movers

Merus Shares Are Up Today: What's Going On?

WIIM

Merus shares are trading higher after the company announced the FDA granted breakthrough therapy designation for Petosemtamab plus Pembrolizumab in PD-L1.

Biotech

General

FDA Grants Breakthrough Therapy Designation For Merus's Petosemtamab Plus Pembrolizumab In PD-L1 Positive Head And Neck Cancer

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Ben Kallo initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Outperform rating and announced a price target of $448. GE Vernova shares closed at $369.65 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Joseph Catanzaro initiated coverage on Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with an Overweight rating and announced a price target of $84. Merus shares closed at $40.26 on Wednesday. <a href="https://www.benzinga.com/quote/MRUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst George Farmer initiated coverage on Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Sector Outperform rating and announced a price target of $102. Viking Therapeutics shares closed at $29.32 on Wednesday. <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Randy Binner initiated coverage on Sunrise Realty Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) with a Buy rating and announced a price target of $15. Sunrise Realty Trust shares closed at $11.47 on Wednesday. <a href="https://www.benzinga.com/quote/SUNS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Hold rating and announced a price target of C$67. <a href="https://www.benzinga.com/quote/FTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1006" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png" alt="" class="wp-image-780880" style="width:412px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png 1006w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-768x386.png 768w" sizes="(max-width: 1006px) 100vw, 1006px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

SUNS

TSX:FTS

VKTX

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Piper Sandler analyst Joseph Catanzaro initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight rating and announces Price Target of $84.

Piper Sandler Initiates Coverage On Merus with Overweight Rating, Announces Price Target of $84

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Merusto Buy

"This manuscript provides comprehensive data on the safety and efficacy of Bizengri and demonstrates the meaningful results observed in the eNRGy trial," said&nbsp;Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "We continue to make significant progress across our clinical pipeline of important and new cancer therapeutic candidates, all from our own Biclonics&nbsp;antibody technologies."

Merus Says New England Journal Of Medicine Published Results Of Registrational Phase 2 eNRGy Trial For Bizengri

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>). Here&#8217;s <a href="https://www.benzinga.com//node/42936564">what you need to know.</a>
What To Know: Biohaven and Merus will to co-develop three antibody-based therapies, utilizing Merus&#8217; Biclonics platform alongside its own technologies. The collaboration includes two existing Merus programs and one in early research. 
Under the agreement, Merus will receive an upfront payment and a licensing fee once the first antibody drug conjugate (ADC) candidate is selected. In addition, Merus will cover the costs of preclinical antibody development, while Biohaven will manage the preclinical ADC development expenses. 
If any therapies progress to commercialization, the companies plan to share development costs jointly.
&#8220;We believe this collaboration with Merus will accelerate our ability to create highly differentiated multispecific ADCs, leveraging Biohaven&#8217;s innovative conjugation and payload technologies to deliver optimized ADCs with the potential to significantly benefit patients across various cancer types through an enhanced efficacy and safety profile,&#8221; added Brian Lestini, President, Oncology of Biohaven.
Related Link: <a href="https://www.benzinga.com/general/travel/25/01/42958773/united-airlines-earnings-preview-could-airline-impress-investors-after-deltas-strong-guidance">United Airlines Earnings Preview: Could Airline Impress Investors After Delta&#8217;s Strong Guidance?</a>
MRUS Price Action: Merus stock closed 7.75% lower on Monday at $40.45, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Photo: Shutterstock

BHVN

What's Going On With Merus Stock Monday?

Merus shares are trading lower. The company announced a  research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

Reported Earlier, Merus And Biohaven Partner to Co-Develop Three Novel Bispecific Antibody Drug Conjugate (ADC) Programs

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

Intraday Update

MVST

PCRX

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

<a href="https://www.globenewswire.com/Tracker?data=NCrzNoU8yG3rqGkuad5oez3SzNsyzo2BctG8WH-FtL0Cds5D7DndYCzk5K4CaTbYNejhAylgOrnJYMb4e1eW1A==">Merus N.V</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics&#xAE;&nbsp;targeting EGFR and LGR5.&nbsp;
The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab&nbsp;monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.

Merus announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $89 to $97.

Citigroup Maintains Buy on Merus, Raises Price Target to $97

Health Care

Press Releases

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Comments

Merus

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO